Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs.
Clin Diabetes
; 39(2): 160-166, 2021 Apr.
Article
in En
| MEDLINE
| ID: mdl-33986569
ABSTRACT
To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from <5% before 2005 to 12.5% in 2019. However, it is still low given its inclusion in the American Diabetes Association's latest guidelines and known limitations of A1C for assessing ongoing diabetes care.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Guideline
Language:
En
Journal:
Clin Diabetes
Year:
2021
Document type:
Article
Affiliation country:
Canadá